AlzChem plans IPO to gain bigger foothold in feed additives

© istock/archix

German chemical company, AlzChem, today announced it plans to go public in the first half of this year.

It said is looking to go down the route of an initial public offering (IPO) in the regulated market of the Frankfurt Stock Exchange. 

“AlzChem’s management, the banking consortium Société Générale and Baader Bank, all feel confident that a capital increase in the range of €40m to €50m is feasible,” said Max Breuer, spokesperson for AlzChem.

He said the company intends to use the IPO as a strategic move to deepen its footprint in the fast growing market for feed additives. 

"The largest part of the proceeds of the €40m to €50m will be used to finance a new production facility at the company’s site in Trostberg, in Germany for specialty chemistry applications such as its feed additive, CreAMINO," said Breuer. 

The company will publish additional details regarding the IPO in due course, he added.  

Operations, financial results

AlzChem has four production sites in Germany, a carbide plant in Sweden, a sales subsidiary in the US and a Chinese subsidiary for raw material purchase and Asian sales.

The company’s operating activities are divided into the business segments of specialty chemicals, basics and intermediates, and others and holding.

Specialty chemicals comprises the manufacture and distribution of chemical products for various end markets, including feed additives under the brand CreAMINO.

In the first nine months of 2016, AlzChem reported sales totaled €250.5m (9M/2015: €248.2m). Of this, 51.1% (€128m) was attributable to the specialty chemicals division. In that period, it added, 40.8% of sales were generated in Germany and 59.2% abroad.

Investments in innovations in the specialty chemicals business segment over the last few years have made a clear contribution to the company's profitability, said the firm.

Greater market penetration

The growing world population is driving the growth of the markets for feed additives, claimed AlzChem, with farming land availability increasingly limited, and, thus, efficient agricultural processes and supply security are becoming increasingly important.

“AlzChem is addressing this development with the feed additive CreAMINO, which animals process into the bodily substance creatine, leading to improved feed utilization. This allows agricultural businesses to reduce the total feed volume required. The use of CreAMINO can therefore lead to cost savings on the part of the animal owners and to a general reduction in the ecological footprint of feed production and transport.

“According to Frost & Sullivan, AlzChem was the dominant player and global market leader in the field of creatine-based feed additives as of 2015.

“In the fourth quarter of 2016, the [US] Food and Drug Administration (FDA) granted approval of a petition filed by the company, enabling it to supply CreAMINO for broiler chickens and turkeys in the US. AlzChem is striving for increased market penetration through the approval of CreAMINO for other species and countries,” noted the German developer.   

AlzChem also cited over 60 patent families and other intellectual property as critical building blocks for its growth trajectory.

Related News

'Feed innovation that is not capital intensive such as antibiotic alternatives based on pre and probiotics or phytogenics is also attracting the money.' © istock/spectrumblue

Show me the money! Ag tech is pulling in venture capital

The German company plans to invest €100m in start-ups with innovative technologies and in specialized funds as part of its VC activities, with a focus on Europe, the US and Asia. © istock/Tuangtong

Evonik tracking Chinese agtech and animal nutrition innovation

© istock.com/Zerbor

EFSA unable to conclude on efficacy of AlzChem additive in breeder hens and piglets

Full steam ahead for US feed firm Phibro on IPO plans

Gas to protein maker UniBio aims to raise $23.5m in IPO

Gas to protein maker UniBio aims to raise $23.5m in IPO

Analyst maps out road ahead for Phibro after IPO: 'It can become the Pfizer of the animal health and nutrition space'

Analyst maps out road ahead for Phibro after IPO: 'It can become the Pfizer of the animal health and nutrition space'

© istock.com

Former Goldman Sachs investment manager joins Calysta as CFO

© istock/cacaroot

Danish study 'validates' single cell protein technology: UniBio

Related Products

See more related products

Submit a comment

Your comment has been saved

Post a comment

Please note that any information that you supply is protected by our Privacy and Cookie Policy. Access to all documents and request for further information are available to all users at no costs, In order to provide you with this free service, William Reed Business Media SAS does share your information with companies that have content on this site. When you access a document or request further information from this site, your information maybe shared with the owners of that document or information.